China Cell Biology Industry Conference & Biopharmaceutical Innovation Cooperation Conference

The China Cell Biology Industry Conference and the Biopharmaceutical Innovation Cooperation Conference (CBIC) will bring together key topics including antibody drugs, stem cells and regenerative medicine, immune cell therapy, cell-based therapeutics, 3D cell culture, cellular multi-omics, organoids, exosomes, target screening, pharmaceutical innovation, next-generation vaccines, gene therapy, oncolytic viruses, and more—focusing on cutting-edge advances in biotechnology, clinical applications, industrialization progress, investment and financing opportunities, industry standardization, and emerging regulatory trends.

The biopharmaceutical industry is one of China’s strategic emerging industries prioritized for development. Currently, China ranks second globally in the pharmaceutical market, behind only the United States, and is undergoing a critical strategic transition from “generic drugs” to “innovative medicines.” Precision medicine is driving a revolution in drug discovery, while advances in genetic technologies and cell engineering are bringing transformative changes to disease treatment. Medical devices are moving toward greater intelligence and standardization, offering novel diagnostic and therapeutic approaches. Meanwhile, emerging biopharmaceutical service sectors—such as contract research organizations (CROs), contract manufacturing organizations (CMOs), third-party testing, and health management—are rapidly expanding, propelling the biopharmaceutical industry into a phase of rapid growth. (Copyright of this content belongs to Juzhan; unauthorized reproduction is prohibited.)

In recent years, national and local governments have introduced a series of policies to foster the development of the bioeconomy. The Bohai Rim region—led by Beijing, Tianjin, Hebei, and Shandong; the Yangtze River Delta—with Shanghai at its core and Jiangsu and Zhejiang as its wings; and the Pearl River Delta—centered on Guangzhou and Shenzhen—have emerged as three major regional hubs for biopharmaceutical innovation, each enjoying distinct competitive advantages in the industry.

The China Cell Biology Industry Conference and the Biopharmaceutical Innovation Cooperation Conference (CBIC) invite leading experts and industry pioneers from academia, innovative pharmaceutical companies, research institutions, hospitals, biotech firms, health management providers, medical aesthetics enterprises, venture capital and private equity firms, industrial parks, trade associations, and government regulatory agencies to convene and jointly explore the current state and future prospects of the sector, sharing new opportunities for industry advancement.

Concurrent with the conference, related thematic exhibitions will showcase the latest products, technologies, and services in the field. By consolidating nationwide biopharmaceutical resources, the event provides participants with a one-stop platform for academic exchange, channel matchmaking, market expansion, and brand promotion, empowering the industry to achieve leapfrog development.

China Cell Biology Industry Conference & Biopharmaceutical Innovation Cooperation Conference tickets are e-tickets. Mainland China visitors must complete online pre-registration with real-name ID verification; overseas visitors must use passport verification; Hong Kong, Macao, and Taiwan visitors must use their travel permit. On site, verify entry with your ID card or by scanning the e-ticket QR code.

Partial exhibitor directory and exhibitor list for China Cell Biology Industry Conference & Biopharmaceutical Innovation Cooperation Conference: 天津天诚新药评价有限公司, 北京阅微基因技术股份有限公司, Thermo Fisher Scientific, J.P. Morgan, SGS, 厦门特宝生物工程股份有限公司, and others. The 2026 edition is expected to feature 500+ exhibiting companies. To obtain the full exhibitor directory (including booth numbers and contact details), please visit the official exhibition website or contact Jufair.